# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and raises the price target from $143 to $151.